Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
11 p, 1.8 MB Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks : A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial / Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Costanzo, Antonio (Humanitas Clinical and Research Center IRCCS) ; de Jong, Elke M. G. J. (Radboud University Medical Center) ; Torres, Tiago (University of Porto) ; Warren, Richard B. (The University of Manchester) ; Wapenaar, Robert (Janssen-Cilag BV (Breda, Països Baixos)) ; Wegner, Sven (Janssen-Cilag GmbH (Neuss, Alemanya)) ; Gorecki, Patricia (Janssen-Cilag Ltd (High Wycombe, Regne Unit)) ; Gramiccia, Talia (Janssen-Cilag SpA (Milà, Itàlia)) ; Jazra, Maria (Janssen-Cilag (París, França)) ; Buyze, Jozefien (Janssen Pharmaceutica NV (Beerse, Bèlgica)) ; Conrad, Curdin (University of Lausanne) ; Universitat Autònoma de Barcelona
Treatment of moderate-to-severe plaque psoriasis with biologics, such as guselkumab, has demonstrated greater efficacy over traditional non-biologic treatments. However, given patient diversity, greater understanding of the relationship between patient characteristics, positive clinical outcomes, and long-term response to biologics is crucial for optimizing treatment choices. [...]
2023 - 10.1007/s40257-023-00816-1
American Journal of Clinical Dermatology, Vol. 25 (october 2023) , p. 315-325  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.